{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:21:28Z","timestamp":1788009688241,"version":"build-2784847793"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.amjcard.2018.11.019","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T16:00:20Z","timestamp":1543075220000},"page":"592-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF)"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars S.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakis","family":"Themistoclakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Melino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3340-4568","authenticated-orcid":false,"given":"Shannon M.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2018.11.019_bib0001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjcard.2016.04.013","article-title":"Relation of nonvalvular atrial fibrillation to body mass index (from the SPORTIF Trials)","volume":"118","author":"Proietti","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0002","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/jce.13428","article-title":"Overweight and obesity in patients with atrial fibrillation: sex differences in 1-year outcomes in the EORP-AF General Pilot Registry","volume":"29","author":"Boriani","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0003","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/STROKEAHA.116.015984","article-title":"Is There an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin k antagonist oral anticoagulant trials","volume":"48","author":"Proietti","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/07853890.2016.1197415","article-title":"Complex relationship of obesity and obesity paradox in heart failure - higher risk of developing heart failure and better outcomes in established heart failure","volume":"48","author":"Alagiakrishnan","year":"2016","journal-title":"Ann Med"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","article-title":"The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review","volume":"106","author":"De Caterina","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"20","key":"10.1016\/j.amjcard.2018.11.019_bib0006","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal directed weight management in an atrial fibrillation cohort: a Long-term Follow-Up StudY (LEGACY Study)","volume":"65","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0007","first-page":"139","article-title":"Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillationa meta-analysis of 626,603 individuals in 51 studies","volume":"1","author":"Wong","year":"2015","journal-title":"JACC: Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0008","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0009","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2015.02.009","article-title":"A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study","volume":"169","author":"Lip","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0012","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED Score. The AMADEUS Trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0013","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0014","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijcard.2005.03.057","article-title":"Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long term success rate","volume":"107","author":"Blich","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2018.11.019_bib0016","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/clc.4960240313","article-title":"Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation","volume":"24","author":"Frick","year":"2001","journal-title":"Clin Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918321003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918321003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:02:07Z","timestamp":1717200127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914918321003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0002914918321003"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.11.019","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}